Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Allyx Therapeutics

Request full access

Innovative oral therapies preserving synapses for neurodegenerative disease patients

New Haven, United StatesFounded 2018Biotech & Life Sciences

About Allyx Therapeutics

Allyx Therapeutics is a biotech startup focused on developing groundbreaking therapies to preserve and protect synapses for individuals suffering from neurodegenerative diseases. The company’s lead compound, ALX 001, is a first-in-class oral therapy that targets the mGluR5 receptor, a critical component in preventing amyloid beta-induced neuronal damage. Founded in 2019 by Yale scientists, biopharma industry veterans, and venture capitalists, Allyx Therapeutics operates in the neurodegenerative disease market, primarily serving patients and healthcare providers. The company is currently in the Series A funding stage and has successfully utilized both public and private non-dilutive funding sources, including grants from the National Institutes of Health (NIH). Allyx Therapeutics generates revenue through the development and eventual commercialization of its proprietary therapies. The company is actively engaged in clinical research, with ongoing Phase 1b trials for ALX 001, and aims to expand its pipeline to address additional neurodegenerative conditions.

Source: Dealroom company data

At a glance

Status
Operational
Employees
5
Open positions
None listed
Dealroom signal
56.9/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC May 2025 $27M $106M Bristol-Myers Squibb · Canaan Partners Israel ↗
GRANT✓Other financing Oct 2024 $3.3M — National Institutes of Health ↗
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Allyx Therapeutics website traffic

Latest recorded traffic for Allyx Therapeutics is 1.3K monthly website visits, down 7.1% over the last three months. Allyx Therapeutics's team grew 0% over the past year.

Latest monthly visits1.3K 3-month web change-7.1% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Allyx Therapeutics in the New Haven ecosystem

Live from Dealroom

The Allyx Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • National Institutes of Health

Series A3 investors entered at this stage

  • Connecticut Innovations
  • Bristol-Myers Squibb
  • Canaan Partners Israel

Other known investors5 additional known investors

Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Allyx Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.